These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3890986)

  • 1. Hepatitis safety of a new prothrombin complex preparation, sterilized according to the method of LoGrippo. Results of a prospective clinical trial.
    Hoppe I
    Blut; 1985 Jun; 50(6):363-8. PubMed ID: 3890986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB).
    Heinrich D; Kotitschke R; Berthold H
    Thromb Res; 1982 Oct; 28(1):75-83. PubMed ID: 7157232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus safety of beta-propiolactone treated plasma preparations. Clinical experiences.
    Heinrich D; Sugg U; Brackmann HH; Stephan W; Lissner R
    Dev Biol Stand; 1987; 67():311-7. PubMed ID: 3649316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective study of posttransfusion hepatitis in cardiac surgery patients receiving only blood or also blood products.
    Tremolada F; Chiappetta F; Noventa F; Valfrè C; Ongaro G; Realdi G
    Vox Sang; 1983; 44(1):25-30. PubMed ID: 6299010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of post-transfusion infection with the hepatitis delta virus. A multicenter study.
    Rosina F; Saracco G; Rizzetto M
    N Engl J Med; 1985 Jun; 312(23):1488-91. PubMed ID: 3990749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [PPSB].
    Ménaché D
    Rev Fr Transfus Immunohematol; 1985 Dec; 28(6):643-58. PubMed ID: 3912930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Risk of hepatitis from conventional pooled PPSB preparations].
    Hoppe I; Maass H
    Dtsch Med Wochenschr; 1982 Dec; 107(51-52):1966-8. PubMed ID: 6816565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of posttransfusion hepatitis.
    Alter HJ; Holland PV; Purcell RH
    Pathobiol Annu; 1980; 10():135-56. PubMed ID: 6777742
    [No Abstract]   [Full Text] [Related]  

  • 9. Viral markers of hepatitis.
    Velasco M
    Lab Res Methods Biol Med; 1983; 7():103-17. PubMed ID: 6413796
    [No Abstract]   [Full Text] [Related]  

  • 10. [Contribution to the task of reducing the incidence of post transfusion non-A, non-B hepatitis].
    Hernández Sánchez MC; Vila Enriquez P; Alvarez Hernández M
    Sangre (Barc); 1989 Jun; 34(3):248-9. PubMed ID: 2503897
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.
    Stevens CE; Aach RD; Hollinger FB; Mosley JW; Szmuness W; Kahn R; Werch J; Edwards V
    Ann Intern Med; 1984 Dec; 101(6):733-8. PubMed ID: 6437308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between guanase activity in donor blood and the incidence of posttransfusional non-A, non-B hepatitis, and a possible method for preventing posttransfusional hepatitis.
    Ito S; Tsuji Y; Iwasaki A; Kitagawa N; Tamura Y; Fujii S
    Hepatology; 1986; 6(5):990-3. PubMed ID: 3093359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis of viral hepatitis: transfusion transmitted disease and the hepatitis B vaccine.
    Holland PV
    Prog Clin Biol Res; 1983; 143():357-67. PubMed ID: 6322200
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatitis B antigen and the liver.
    Mihas AA; Conrad ME
    Medicine (Baltimore); 1978 Mar; 57(2):129-50. PubMed ID: 74789
    [No Abstract]   [Full Text] [Related]  

  • 15. [Passive prophylactic immunisation against post-transfusion hepatitis by immunoglobulin preparations: a prospective clinical study].
    Schumacher K; Maerker-Alzer G; Kleinau T; Hügel W; Dalichau H; Dienst C; Mitrenga D
    Dtsch Med Wochenschr; 1982 Oct; 107(39):1459-64. PubMed ID: 6811237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of screening tests for hepatitis B antigen and transaminase in blood service institutions for the prevention of viral hepatitis].
    Golosova TV; Burlev VA; Margolina AN; Gorzejsi I; Novák J
    Probl Gematol Pereliv Krovi; 1979 Mar; 24(3):47-8. PubMed ID: 372947
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood-transmitted and clotting-factor-transmitted non-A, non-B hepatitis. Clinical differences and evolution.
    Tremolada F; Loreggian M; Antona C; Cirillo F; Noventa F; Realdi G
    J Clin Gastroenterol; 1988 Aug; 10(4):413-8. PubMed ID: 3138304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inactivation of non-A, non-B virus infectivity by a beta propiolactone/ultraviolet irradiation treatment and Aerosil adsorption procedure used for preparation of a stabilized human serum.
    Prince AM; Stephan W; Brotman B
    Vox Sang; 1984; 46(2):80-5. PubMed ID: 6322448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBsAG positive reactivity in man not due to hepatitis B virus.
    Coursaget P; Yvonnet B; Bourdil C; Mevelec MN; Adamowicz P; Barrès JL; Chotard J; N'Doye R; Diop Mar I; Chiron JP
    Lancet; 1987 Dec; 2(8572):1354-8. PubMed ID: 2446096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Currently available means for the prevention of post-transfusion hepatitis and criteria for their application].
    Bedarida G; Cambiè G; D'Agostino F; Sterza G
    Ric Clin Lab; 1984; 14 Suppl 1():37-60. PubMed ID: 6429830
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.